Much-anticipated data from Vertex Pharmaceuticals Inc.'s first Phase III trial of hepatitis C virus (HCV) protease inhibitor telaprevir lived up to investors' high expectations. (BioWorld Today)

Biogen Idec Inc. and Abbott kicked off a Phase III trial comparing their anti-IL-2 antibody daclizumab to Biogen's Avonex (interferon beta-1a) in relapsing-remitting multiple sclerosis. (BioWorld Today)